Astaxanthin before retrieval: better embryos, no pregnancy signal yet

Design

Triple-blind, placebo-controlled pilot randomised trial

Population

50 women with polycystic ovary syndrome and anovulatory infertility; 44 completed (21 astaxanthin, 23 placebo)

Primary outcome

Granulosa-cell autophagy signalling, with ovarian response and cleavage-stage embryo quality

Effect

Total and metaphase II oocyte yield higher after adjustment; top-ranking embryo rate and cryopreservable embryos higher; pregnancy outcomes not significant

Fifty women with anovulatory infertility related to polycystic ovary syndrome were randomised, triple-blind, to astaxanthin 12 mg daily or placebo for six weeks before oocyte retrieval; 44 completed (21 astaxanthin, 23 placebo). The trial was designed around a mechanism - whether astaxanthin alters autophagy signalling in granulosa cells - with ovarian response and cleavage-stage embryo quality as the clinical outcomes.

The mechanistic endpoints moved. Astaxanthin increased expression of autophagy-related gene 7, enhanced autophagy flux and reduced apoptosis, with a non-significant trend towards greater activation of AMP-activated protein kinase. Clinically, total oocyte yield and mature metaphase II oocyte yield were both higher with astaxanthin after adjustment for age, body mass index and anti-Mullerian hormone. Oocyte maturity rate was higher before adjustment but not after. Top-ranking embryo rate and the number of embryos suitable for freezing were both higher after adjustment. Pregnancy outcomes were numerically higher and not statistically significant.

What to do with this is nothing, yet. Forty-four women is a pilot, the authors call it one, and the endpoint patients care about did not reach significance. It is worth knowing because astaxanthin is sold over the counter and women undergoing IVF ask about supplements constantly - the honest answer is that a small trial found better laboratory outcomes and no demonstrated difference in pregnancy.

• Ask what over-the-counter supplements a woman is taking before a cycle; many will not mention them unprompted
• Do not start astaxanthin on the strength of a pilot with 44 completers
• If a patient is already taking it, there is no safety signal here to act on either
• Distinguish embryo quality from live birth when discussing any adjuvant in IVF
• Note that the oocyte maturity rate lost significance once age, body mass index and AMH were accounted for

Why it matters

Adjuvants in IVF are judged on live birth, and this trial does not reach it.

Don't overread it

A pilot trial with mechanistic primary endpoints; laboratory outcomes improved, pregnancy outcomes did not reach significance.

The statistics, in plain English

The pattern where a result is significant before adjustment and not after - as happened to oocyte maturity rate - usually means the apparent effect was being carried by a difference between the groups in age, body mass index or ovarian reserve rather than by the drug. That is the adjustment doing its job. Conversely, effects that survive adjustment in a trial this small are still fragile: with 21 against 23 completers, a handful of women moving between categories can change which outcomes clear significance. 'Numerically higher but not statistically significant' for pregnancy means the trial was far too small to detect a difference that would matter, not that there is none.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.